Approximately 15% of all human tumors harbor mutant KRAS, a membrane-associated small GTPase and a notorious oncogene. Somatic mutations that render KRAS constitutively active lead to uncontrolled cell growth, survival, proliferation, and eventually cancer. KRAS is thus a critical anticancer drug target. However, despite aggressive efforts in recent years, there is no drug on the market that directly targets KRAS. In the current work, we combined molecular simulation and high-throughput virtual screening with a battery of cell-based and biophysical assays to discover a novel, pyrazolopyrimidine-based allosteric KRAS inhibitor that exhibits promising biochemical properties. The compound selectively binds to active KRAS with submicromolar affinity, slightly modulates exchange factor activity, disrupts effector Raf binding, significantly reduces signal transduction through mutant KRAS and inhibits cancer cell growth.
Introduction
Somatic mutations in RAS proteins are associated with about 16% of all human cancers (1, 2) .
KRAS is the most frequently mutated RAS isoform, accounting for 85% of all RAS-related cancers (1, 2) . Cellular KRAS is tethered to the inner surface of the plasma membrane by a farnesylated polybasic lipid anchor (3) , and cycles between active guanosine tri-phosphate (GTP)-and inactive guanosine di-phosphate (GDP)-bound conformational states (4) . GTPase activating proteins (GAPs) facilitate hydrolysis of GTP by KRAS while guanine nucleotide exchange factors (GEFs) catalyze GDP dissociation (4) (5) (6) . Upon activation by receptor tyrosine kinases such as epidermal growth factor (EGF) receptors, GEFs are recruited to KRAS and initiate exchange of GDP for GTP. Active KRAS interacts with effectors such as Raf in the MAPK pathway and PI3K in the AKT pathway (7) , driving cell growth and proliferation (8, 9) . In a regulated RAS cycle, signaling is turned off upon GTP hydrolysis. Oncogenic mutations that impair its GAP-mediated or intrinsic GTPase activity render KRAS constitutively active and thereby cause uncontrolled cell growth/proliferation leading to cancer (1, 2) . Mutant KRAS is therefore a highly sought-after anticancer drug target (10, 11) .
Despite decades of efforts, however, drugging KRAS (and RAS proteins in general) remains an unrealized goal (12) . Among the many challenges, conservation of the nucleotide-binding site among a diverse group of small GTPases (4, 13) , and the high (picomolar) affinity of RAS for its endogenous ligands GDP or GTP, are arguably the most significant. These issues made competitive inhibition impractical and avoiding off-target effects difficult. Thus, along with efforts at indirect RAS inhibition by targeting its interaction partner proteins (14, 15) or membrane localization (16, 17) , development of direct allosteric KRAS inhibitors is currently a major focus of many laboratories (18) . Proof-of-principle studies have established the allosteric nature of RAS (11, 19, 20) , and discovered several allosteric small-molecule KRAS binders (21) (22) (23) (24) (25) .
Moreover, a number of recent reports described molecular fragments (23) , small-molecules (18, (24) (25) (26) , peptidomimetics (27, 28) and monobodies (29) that bind KRAS and modulate its functions in various ways. While this paints an optimistic picture of the prospects of allosteric KRAS inhibition, to the best of our knowledge none of these compounds has made it to clinical trial. Recent efforts toward developing covalent GDP analogues (30) or other small-molecule ligands (31) targeting G12C mutant KRAS may have a better chance of eventually treating specific tumor types (18) . However, their application is likely limited to a few cancer cases such as small cell lung cancer (10) . We believe non-covalent allosteric inhibition will be needed to target some of the most important mutations in KRAS including G12D, G12V, G13D and Q61H that are critical in biliary tract, small intestine, colorectal, lung and pancreas cancers (2, 10) .
Together, these four mutations appear to account for greater than 78% of all KRAS-associated cancers (10) .
In previous reports, we described four allosteric ligand-binding sites on KRAS using a range of computational approaches (32, 33) , including molecular dynamics (MD) simulations to sample transient conformations with open allosteric pockets (34) (35) (36) . Among these, pocket p1 was the best characterized and is well established as a suitable target with many crystal structures of p1-bound ligand-KRAS complexes available in the protein data bank (PDB). In the current work, we combined MD simulation with a range of biophysical and cell assays to discover and characterize a novel class of inhibitors that bind to the p1 pocket with sub-micromolar affinity and abrogate signaling primarily by directly inhibiting the interaction of KRAS with effector proteins.
Materials and Methods

Molecular dynamics simulation and allosteric pocket analysis Most oncogenic RAS
mutants are constitutively active because their ability to hydrolyze GTP is compromised (37, 38 ). An inhibitor that selectively targets GTP-bound mutant RAS would therefore be desirable.
However, there was no ligand-free high-resolution experimental structure of GTP-bound KRAS ( GTP KRAS) when we started this project in 2014, and our target pocket p1 (see below) was closed or was too small in the available GDP-bound KRAS ( GDP KRAS) structures. Therefore, we used MD simulation to generate an ensemble of GTP KRAS structures with open p1. The initial structure for the simulation was a 5'-guanosinediphosohate-monothiophosphate (GSP)-bound KRAS G12D X-ray structure from the PDB (ID 4DSO) with benzamidine bound at p1 and glycerol between helices 2 and 3 (23) . After converting GSP to GTP, removing all other molecules except crystal waters and the bound Mg 2+ , adding hydrogen atoms and solvent, minimization and restrained simulation, we conducted a 300 ns production run using an identical protocol to that described in a recent report (39) . The trajectory was analyzed in terms of volume and other features (such as numbers of hydrogen bond donors and acceptors) of our target pocket p1, and the conformation with the most open p1 was selected for virtual screening of ligand libraries.
High throughput virtual screening Six million compounds from the Drugs Now subset of the ZINC (40) database were docked into pocket p1 of our MD-derived KRAS G12D structure (Fig 1A, see also Fig S1) . Gasteiger charges and atomic radii were assigned using AutoDock Tools, and a first round of docking was conducted with AutoDock (41) as implemented in the parallelization routine DOVIS (42) . We used the flexible ligand option with 1.0 Å spacing, along with a Lamarckian search with 150 generations and 1,000,000 energy evaluations. The top ~4000 compounds with energy score ≤ -6.8 kcal/mol were re-screened with VINA v1.1.2 (43) with exhaustiveness set to 12 and energy range to 4. The top 500 hits in each screen were then evaluated in terms of their ability to form close contact, salt bridge, hydrogen bonding, hydrophobic, cation-π, π-π and π-stacking interactions with the protein, using distance and angle cutoffs recommended by Durant et. al. (44) . We found 58 ligands that score well in the majority of these metrics and experimentally tested 11 that are listed in Fig S2A . (hereafter GST-Raf RBD ) to monitor RAS-Raf interaction. To prepare GST-Raf RBD bound to agarose beads, bacteria (BL21) transfected with a previously cloned GEX plasmid were grown in selection media to OD levels of 0.5-1.0 before protein expression was initiated with IPTG
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(1:1000). After 4 h, the sample was centrifuged at 6000 rpm for 5 min at 4°C, the pellet was resuspended with PBS containing 5 mM EGTA, 1% Triton X-100, PIC 1:50 and PMSF 1:100, and cells were lysed with cycles of freezing and thawing. The lysate was sonicated to breakup DNA, and pelleted. The supernatant was incubated with glutathione agarose (Pierce™) beads that bind to GST-Raf RBD . For all pull-down experiments, equal volumes of lysates from BHK cells expressing GFP-RAS were incubated for 2 h at 4°C with GST-RBD beads plus control DMSO or compound. Then samples were washed with Tris buffer (50 mM Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 0.1% Trition X-100 and protease inhibitors) and immunoblotted with anti-GFP (Cell Signaling) and anti-GST (Santa Cruz Biotechnology) antibodies.
Fluorescence lifetime imaging (FLIM)-fluorescence resonance energy transfer (FRET)
FLIM-FRET experiments were carried out using a lifetime fluorescence imaging attachment (Lambert Instruments, The Netherlands) on an inverted microscope (45 Fluorescein (lifetime = 4 ns) was used as a lifetime reference standard. Cells were imaged with a Plan Apo 60X 1.40 oil objective using an appropriate GFP filter set. The phase and modulation were determined from 12 phase settings using the manufacturer's software.
Resolution of two lifetimes in the frequency domain was performed using a graphical method (46) mathematically identical to global analysis algorithms (47, 48) . The analysis yields the mGFP lifetime of free mGFP donor (t 1 ), and the mGFP lifetime in donor/acceptor complexes (t 2 ). FLIM data were averaged on a per-cell basis. In a separate set of experiments, BHK cells co-expressing GFP-KRAS G12D or GFP-HRAS G12V with empty vector pC1 or mCherry-RBD were treated with vehicle DMSO or 1 uM and GFP fluorescence was measured as described above. Experiments were conducted with minimal light and the reaction was monitored for 2 h at room temperature. Fluorescence intensities were normalized at 120 s and the traces were fit with linear or single exponential functions (Igor Pro, Wavemetrics). Optima plate reader (excitation: 485 nm, emission: 520 nm) at room temperature. GST-tag was used to increase the weight of Raf RBD for a greater polarization. The dissociation constant for KRAS-Raf binding was determined using a quadratic ligand binding equation (50) .
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Results and Discussion
Initial hits from molecular modeling and high-throughput virtual screening We conducted in silico screening of compounds from the ZINC database (40) targeting pocket p1 on an MDderived structure of GTP KRAS G12D . This pocket is located between the functionally critical switches 1 (residues 25-40) and 2 (residues 60-75), and encompasses residues 5-7, 37-39, 50-56, 67 and 70-75 (Figs 1A, S1). Many of these residues, including residues 37-39 on the effector binding loop and residue 71 on switch 2, participate in interaction with effectors and/or
GEFs. Therefore, we reasoned that a p1-targeted ligand could disrupt either or both of these interactions. However, p1 was fully or partially closed in the available KRAS structures including the holo forms, which were generally bound to small (<160 Da) ligands ( Fig S1) . We wanted to
have a more open conformation in order to dock a wide range of "drug-like" molecules spanning the ~150-500 Da molecular weight common in marketed drugs. We therefore conducted MD simulation to generate an ensemble of GTP KRAS G12D structures with open p1. Analysis of the trajectory yielded 119 and 219 Å 3 as the mean and maximum volumes of pocket p1, respectively. We performed retrospective comparison of the MD conformer with the most open p1, which we used for molecular docking, with currently available GTP (or analogue)-and GDPbound crystallographic KRAS structures ( Fig S1) . We observed three distinct groups of conformers that differ mainly in the orientation of helix 2. In one group, the orientation of helix 2 is such that pocket p1 is nearly or completely closed (orange). All of these structures are GDPbound and are dominated by structures in complex with covalent ligands. In the second, sampled by both GDP-and GTP-bound KRAS, movement of helix 2 toward helix 3 opens up the pocket to some extent. In group 3, helix 2 moved even farther away from the core beta-sheet, allowing for a more open p1. Our MD-derived conformer belongs to the third group and exhibits the largest displacement of helix 2, which, together with side chain re-orientations, allowed for a wider pocket p1 ( Fig S1) . We used this snapshot to conduct an initial screen of 6,000,000
compounds, followed by a secondary screen of the top ~4000 (see Methods). Analysis of the top 500 ligands in each screen yielded a consensus prediction of 58 initial hits. Eleven of these were purchased and tested in cells (Fig S2A) . 
L6
Cell signaling assays identify compound 11 as a promising initial hit Western analysis was used to quickly assess the potential impact of our predicted hits on MAPK signaling, a major pathway mediated by KRAS. Specifically, we monitored ERK1/2 phosphorylation levels (p-ERK)
in BHK cells stably expressing KRAS G12D treated with vehicle (DMSO), the MEK inhibitor U0125
(U) or compound at four different concentrations (1-100 μM). The results showed that the majority of the predicted hits have no effect while few (e.g. 4) increase rather than decrease p-ERK levels (Fig S2B) . Compounds 9 and 11, on the other hand, decreased p-ERK levels at concentrations ≥ 50 μM and ≥1 μM, respectively. To verify the latter observation, we repeated the experiments in an expanded concentration range starting from 0.1 μM. As in the first screen, compound 11 dose-dependently decreased p-ERK levels, leading to a ~50% reduction at 5 μM ( Fig S2C) . However, compound 9 increased p-ERK levels at 25 and 38 μM in contrast to the decrease observed at higher concentrations (Fig S2B) . Although a similar increase and then decrease of KRAS signaling upon increasing ligand concentration has been observed before (49, 52) , we selected the more potent and monotonously dose-dependent compound 11 for further analysis. Figures 1B and 1C show the chemical structure and the predicted complex of compound 11 with KRAS, suggesting that the ligand potentially forms multiple favorable interactions with residues in the p1 pocket. Figure 1D shows that the compound binds to the catalytic domain (residues 1-166)
Compound 11 binds to WT and oncogenic KRAS mutants with high affinity
GTP KRAS WT with a K D = ~ 0.3 µM, suggesting a very tight binding rarely seen in primary screens.
The compound has a very similar affinity (K D = ~0.4-0.7 µM) for oncogenic mutants KRAS G12D , KRAS G12C and KRAS Q61H in the GTP state (Fig 1D) . However, no binding or very weak binding was detected for KRAS WT and KRAS G12D in the GDP state, HRAS WT and NRAS WT in both their GDP and GTP-bound forms, or to our control Rap1b (Fig S3) , a RAS-related small GTPase with homologous structure. Few weak-affinity non-covalent binders that exhibit selectivity toward GDP-or GTP KRAS have been reported (23) (24) (25) . However, to the best of our knowledge, compound 11 is the first small molecule to selectively bind to KRAS GTP with a nanomolar affinity.
In the docked pose (Fig 1C) , the 1-piperazineethanol moiety occupies an electronegative cleft near D54 and D38, potentially donating hydrogen bonds to the side chain and backbone atoms of E37. The methylated pyrazolopyrimidine core sits in a trench on top of V7 and L56 with its methyl group pointing towards I55 while the pyrimidine-bound benzene ring occupies the space between the central beta sheet (β1-β3) and helix 2, and makes π-stacking interaction with Y71.
The pyrazol-attached benzene is buried deep in a tight pocket, stabilized primarily by van der Waals (vdW) interactions with side chain carbon atoms of V7, L6 and K5. These interactions are common in the majority of our predicted hits listed in Fig S2A . Therefore, we propose that, in addition to potential induced-fit effects, compound 11's preference for GTP-bound KRAS may be due to conformational differences of these residues in GTP RAS versus GDP RAS (4).
Comparison of available GDP-and GTP-bound RAS structures supports this conclusion. For example, pocket p1 is partially occluded by helix 2 in a large number of GDP-bound KRAS ( Fig   S1) and HRAS (Fig S4) (Fig 3, right) . We found no significant effect on the phosphorylation of these effectors and hence signaling via the MAPK pathway. Similarly, no statistically significant effect on p-AKT levels was observed even though H-Ras is a major driver of the AKT pathway. As a control, treatment of the HRAS G12V -expressing BHK cells with a 10 μM of our control U (the MEK inhibitor U0126) almost completely abolished MAPK signaling (Fig 3) . We tested compound 11's effect on the proliferation of four lung and four oral cancer cell lines and found that the KRAS-expressing lung cancer cells, particularly those with mutant KRAS, are more sensitive to the compound than the HRAS-expressing oral cancer cells (Fig 4A) is 30-35%. In summary, the cell signaling and proliferation assays indicate that compound 11 selectively inhibits signaling through mutant KRAS, consistent with its significant effect on KRAS-Raf interaction (Fig 2) . 
Mechanism of action and optimization route for pyrazolopyrimidine-based KRAS inhibitors
In addition to its effect on effector binding, compound 11 also slightly reduced the rates of both intrinsic and SOS-mediated GDP/GTP exchange reactions of KRAS, as well as SOS-mediated GDP release (SI text and Fig S5) . To identify the chemical fingerprints of compound 11 responsible for its high-affinity binding and effect on KRAS function, we studied compounds 12 and 13. Obtained from similarity searches based on 11, these analogues provided valuable insights into the mechanism of action of our pyrazolopyrimidine-based ligand. In compound 12, the 1-piperazineethanol functional group of 11 is replaced by 1-methylpiperazine (Fig 5A,B) , making it more hydrophobic and less soluble in DMSO. This compound slightly reduced p-ERK
A B
levels at a higher concentration of 2 μM (Fig 5C) but it is nearly as effective as 11 in inhibiting proliferation of lung cancer cells (Fig 5D) . However, it has no effect on p-cRaf levels (Fig 5C) or on KRAS-Raf interaction as assessed by FLIM-FRET (Fig 5E) , suggesting a potentially different mechanism of inhibition than compound 11, or an off-target effect. The predicted binding mode of 12 is similar to that of 11, but it lacks the capacity for hydrogen bonding interactions with residues at the effector-binding loop (Fig 5B) . Together, these results suggest that the hydroxymethyl group on the piperazine ring, which in compound 11 is predicted to interact with residues in the effector-binding loop (Fig 1C) , plays a crucial role in disrupting KRAS-Raf interaction and/or in modulating binding to KRAS.
Despite its several attractive features, solubility issues made compound 12 difficult to work with; a compound with a better solubility profile would be desirable. Also, we believe a derivative that preserves 11's effectiveness in inhibiting effector binding would make for a better lead compound. As shown below, compound 13 ( Fig 6A,B) satisfies both of these conditions. It has a methyl group attached to the pyrimidine in place of the benzene ring found in 11, which makes it less hydrophobic and readily soluble in DMSO and other common solvents. Therefore, we measured the K D of the interaction of compound 13 with G12D and other KRAS mutants using
MST. The results summarized in Fig 6C show that this compound has a 6.5-7.1-fold weaker affinity for KRAS than compound 11. Similar to compound 11, however, 13 does not bind to GDP KRAS WT or GDP KRAS G12D . Comparison of the docked poses of 11 ( Fig 1C) and 13 (Fig 6B) suggests a potential rationale for the observed differences in binding affinity. The benzene ring of compound 11 is involved in a T-shaped π-stacking interaction with the side chain of Y71, which is replaced by the much smaller methyl in 13. This suggests a critical role for the phenyl ring on the pyrimidine core for potency, providing a useful clue for future optimization efforts. We then used fluorescence polarization and pull-down assays to test the functional implication of the modification in 13 relative to the parent compound 11. Fig 6D shows that 20 µM of 13 disrupts the interaction of KRAS with GST-Raf RBD as effectively as the parent compound. Our pull-down assay led to the same conclusion: 13 disrupts KRAS G12D -Raf RBD interaction (Fig 6E) .
These results demonstrate that modifications can be made on the pyrazolopyrimidine core to optimize for potency without compromising effect on effector binding. This conclusion is supported by our structural analysis of the predicted ligand/KRAS complexes ( Figs 1C and 6B ), which shows that 11 and 13 likely make identical contacts with residues at the effector-binding region via their piperazine ring and especially the piperazineethanol group. This is important because, as we have shown using 12, modification in this part of the ligand causes loss of effect on Raf binding. We then wondered if interaction with switch 2 residues or lack thereof may play a role in nucleotide release, because the conformation of many switch 2 residues, such as Y71
and Y64, differs between free and GEF-bound RAS (54, 55) . To test this, we measured the intrinsic and SOS-dependent rates of labeled-GDP release in the absence and presence of 13.
We found that, indeed, replacing the benzene ring on the pyrimidine core by methyl dramatically altered the effect on nucleotide release. Whereas 11 had no effect on intrinsic and only modestly decreased the rate of SOS-mediated nucleotide release (Fig S5) , 13 dramatically increased both rates (Fig 6F) . This result suggests that interaction with switch 2 residues including Y71 may determine how a p1-bound ligand affects GEF activity. The results also provided strong support for the reliability of the predicted ligand-KRAS complex structures, and offered a viable route for additional modifications in future optimization efforts. Rates were calculated using single exponential fits starting a 120 s. 
Concluding Discussion
Finding a direct inhibitor of KRAS remains a major challenge in the search for cancer therapy.
Previous attempts at preventing membrane binding of KRAS by farnesyl transferase inhibitors failed in clinical trials. More recent efforts focused on the dynamics of RAS revealed allosteric pockets suitable for binding of small molecules (32, 35) . Several small-molecule ligands that bind to some of these pockets and disrupt interaction with GEFs or effectors have been discovered (21) (22) (23) (24) (25) . However, thus far none of these ligands have led to a viable lead compound. In the current work, we combined MD simulation to generate a KRAS conformation with open pocket p1 and virtual screening to identify potential hits, followed by biophysical and cell biological experiments for validation. We have discovered a novel high-affinity KRAS It has a pyrazolopyrimidine core rather than an indole or imidazole ring typical in published ligands. Also, 11 is relatively large (415 Da) with its pyrazol ring methylated and benzylated and its pyrimidine ring beta-modified by benzene and 1-piperazineethanol. This allowed it to make more extensive predicted contacts with KRAS p1 residues than is common in most of the published ligands (Fig 1C) . 11 selectively binds to GTP KRAS with submicromolar affinity but not to GDP-bound KRAS, nor to GDP-and GTP-bound NRAS or HRAS (Fig 1, S3) . It inhibits MAPK signaling (Fig 3) and proliferation of mutant KRAS-expressing but not HRASexpressing cancer cells (Fig 4) . Moreover, we used fluorescence polarization, pull-down and FLIM-FRET assays to demonstrate that compound 11 inhibits MAPK signaling primarily by abrogating interaction with effector proteins (Fig 2) , in contrast to many published KRAS ligands that mainly affect GEF activity (22) (23) (24) . At high concentration, 11 exhibits a small effect on intrinsic and GEF-catalyzed guanine nucleotide exchange rates (Fig S5) , but the effect is too small at concentrations used in the cell-based assays to explain the significant inhibitory activity of the compound. For example, there is a maximum of ~5% reduction in the rates of both intrinsic and SOS-mediated nucleotide release or exchange reactions at 1 μM of 11. In contrast, the p-ERK levels dropped by about 50% after a 3 h treatment using the same concentration of compound (Fig 3) .
The above conclusions are also supported by data from comparative analyses of compound 11
and its analogues 12 and 13. Compound 13 retains the effect of the parent compound on Raf binding even though it has a weaker (low µM) affinity for KRAS. Intriguingly, 13 accelerates both intrinsic and SOS-mediated rates of nucleotide release, in contrast to 11 which has no effect on the intrinsic and only modestly decreases the SOS-mediated reaction rate. Compound 12 has no effect on KRAS/Raf interaction and displays some inhibitory activities via an unknown mechanism. The distinct behavior of the derivatives and the parent compound, especially 11
and 13 for which we have data for direct KRAS binding, suggest altered protein-ligand interactions. We propose that the piperazineethanol group interacts with switch 1 of KRAS and plays a critical role in abrogating effector binding, whereas the potentially switch 2-interacting nonpolar moieties attached to the pyrazolopyrimidine core modulate GEF activity and contribute to high-affinity binding. These insights provide ideal starting points for further optimization of our highly promising lead compounds. 
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Data availability statement
The data that support the findings of this study including MD-derived coordinates of KRAS used for docking are available from the corresponding author upon reasonable request. -(5F2E, 4TQA, 4QO3, 4OBE, 4M1T, 4LYJ, 4LV6, 4EPY,  4EPR, 6ASE, 6ARK, 5WHD, 5WHA, 5W22 , 5VBM, 5V9U, 5V9L, 5V6V, 5UQW) and 4 GTP-or GTP analogue-bound KRAS X-Ray structures (5UK9, 5USJ, 4DSO, 6BP1). KRAS structures co-crystalized with proteins or peptides were not considered; all others have been included. Nearly half (eight) of the GDP structures contain covalent ligands targeting KRAS G12C in which pocket p1 between switch 2 and the b1-b3 region is narrowed (orange). Based on the orientation of helix 2, three groups of conformations can be observed in the GDP structures, two of which also are sampled by the GTP structures. (Bottom) Displacement of helix 2 toward helix 3 and side chain reorganizations expanded pocket p1 (described by residues 5-7, 37-39, 50-56, 57-75 shown in surface representation in green; the expansion of a small hydrophobic pocket, originally occupied by benzamidine, during the MD simulation is highlighted in light green and circled in red). Five examples were shown illustrating cases where the ligand has no effect (compounds 1 and 2), increases p-ERK levels (compound 4) or decreases p-ERK levels (compounds 5 and 9). This assay was used as a primary screen to quickly assess the potential of a ligand to qualitatively affect the MAPK pathway; for the sake of efficiency, we did not measure total protein. (C) Representative Western blots (top: p-ERK (upper) and total GFP-KRAS G12D (lower), the latter serving as loading control), and their quantification (bottom) for compounds 9 and 11 for which the Western analysis was repeated in an expanded concentration range. The reduction in p-ERK levels of compound 11-treated cells is not due to reduction in total ERK levels, as shown in Fig 3 of the main text. Data are averages over three independent experiments and error bars represent standard error. * = p < 0.02; ** = p < 0.005. Figure S1 (Fig 1 main text) ). This suggests that the conformation of the full-length construct in solution is likely different from the isolated catalytic domain or cellular full-length KRAS (e.g., the p1 pocket could be partially occluded by the HVR in solution, which in the cell would have been engaged by the plasma membrane). Therefore, unless explicitly stated otherwise, we refer to the isolated catalytic domain throughout this manuscript when describing biophysical measurements. Figure S4 . Alignment of the MD-derived KRAS conformer used for docking (blue) with 9 GDP-(1XJ0, 1ZVQ, 2CE2, 2CLD, 2QUZ, 3LO5, 4L9S, 4Q21, 5VBE) and 27 GTP-or GTP-analoguebound HRAS X-ray structures (1ZW6, 2CL6, 2CL7, 2EVW, 3I3S, 3K8Y, 3K9N,3KKM, 3KKN, 3RRY, 3TGP, 4DLR, 4DLS, 4DLT, 4EFN, 4XVQ, 5B2Z, 5B30, 5VNZ, 5WDP, 5WDQ, 5X9S, 6Q21). HRAS structures co-crystalized with proteins or peptides were not considered; all others have been included. As in KRAS, the orientation of helix 2 modulates the accessible space between the b1-b3 region and switch 2 but there is no obvious difference between the KRAS and HRAS structures at the global level. There aren't as many experimental structures for NRAS. Figure S8 shows time-dependent decreases and increases of fluorescence intensity as a labeled-nucleotide dissociates from and binds to KRAS WT , respectively. Compound 11 slightly reduced the rates of both intrinsic and SOS-mediated nucleotide exchange reactions, as well as the SOS-dependent (but not intrinsic) release of labeled-GDP. In particular, 11
Effect of compound 11 on intrinsic and GEF-dependent nucleotide release and exchange reactions
decreased the intrinsic rate of nucleotide exchange by ~10-fold at >10 µM (Fig S5, top-left) , but it has no effect on intrinsic nucleotide release (Fig S5, bottom-left) . The latter is consistent with our observation from MST that 11 does not bind to GDP KRAS WT with high affinity. Since GTP hydrolysis is unlikely to occur within the timescale of our experiments (2, 3), a plausible interpretation of the former would be compromised GTP loading. This is possible if, for example, the ligand binds to the nucleotide free 'transition state' conformation of KRAS and induces reorganization of active site residues. This is supported by the fact that 11's effect on the rate of nucleotide exchange is significantly smaller (only a 1.1-fold decrease, Fig S5 top-right We note that all of the effects we observed on reaction rates are much smaller than those in KRAS-Raf interaction. Nonetheless, they are statistically significant and dose-dependent, suggesting that compound 11 may modulate KRAS activation through multiple mechanisms, with the dominant effect being on effector binding. 
